Mesalazine-associated acute tubulointerstitial nephritis in a patient with spondylarthropathy

New Zealand Medical Journal

Volumn 118, Issue 1222, 2005, Pages

  Sari, Ismail ^a   Birlik, Merih ^a   Cavdar, Caner ^a   Sarioglu, Sulen ^a   Akpinar, Hale ^a   Onen, Fatos ^a   Akkoc, Nurullah ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

MELOXICAM; MESALAZINE; CREATININE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ANEMIA; ANOREXIA; ARTICLE; BACKACHE; BLOOD CULTURE; CASE REPORT; FEVER; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY DYSFUNCTION; LEUKOCYTOSIS; MALAISE; MALE; NEPHROTOXICITY; PROTEINURIA; SPONDYLOARTHROPATHY; ULCERATIVE COLITIS; URINE CULTURE; ACUTE DISEASE; BLOOD; CHEMICALLY INDUCED DISORDER; ENTERITIS; MIDDLE AGED; TREATMENT OUTCOME;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CREATININE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MESALAMINE; MIDDLE AGED; NEPHRITIS, INTERSTITIAL; SPONDYLARTHROPATHIES; TREATMENT OUTCOME;

EID: 27244435677     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Margetts PJ, Churchill DN, Alexopoulou I. Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine. J Clin Gastroenterol. 2001;32:176-8.
2. Elseviers MM, D'Haens G, Lerebours E, et al. Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy? Clin Nephrol. 2004;61:83-9.
3. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34:1218-27.
4. Corrigan G, Stevens PE. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther. 2000;14:1-6.
5. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003;17:29-42.
6. Thomson GT, Thomson BR, Thomson KS, Ducharme JS. Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies. J Rheumatol. 2000;27:714-8.
7. Dekker-Saeys BJ, Dijkmans BA, Tytgat GN. Treatment of spondyloarthropathy with 5-aminosalicylic acid (mesalazine): an open trial. J Rheumatol. 2000;27:723-6.
8. Frandsen NE, Saugmann S, Marcussen N. Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Nephron. 2002;92:200-2.
9. Novis BH, Korzets Z, Chen P, Bernheim J. Nephrotic syndrome after treatment with 5-aminosalicylic acid. BMJ (Clin Res Ed). 1988;296:1442.
10. World MJ, Stevens PE, Ashton MA, Rainford DJ. Mesalazine-associated interstitial nephritis. Nephrol Dial Transplant 1996;11:614-21.
11. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions reevaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51:536-9.
12. Van Staa TP, Travis S, Leufkens HG, Logan RF. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology. 2004;126:1733-9.